Roivant Sciences (ROIV) Set to Announce Quarterly Earnings on Monday

Key Points

• Roivant Sciences is expected to report Q2 2027 earnings before Monday’s market open. Analysts forecast a loss of $0.3666 per share and revenue of $4.14 million; the earnings call is scheduled for November 9, 2026, at 8:00 a.m. ET.
• The company’s previous quarter exceeded EPS expectations but missed revenue estimates, reporting a $0.26 per-share loss and $1.44 million in revenue. Analysts project full-year and next-year losses of $2.00 and $2.23 per share, respectively.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $46.55 versus the stock’s $36.91 opening price. However, insiders have sold 1.82 million shares worth approximately $66.2 million over the past three months.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) is expected to post its Q2 2027 results before the market opens on Monday, November 9th. Analysts expect Roivant Sciences to post earnings of ($0.3666) per share and revenue of $4.14 million for the quarter. Investors are encouraged to explore the company's upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:00 AM ET.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. On average, analysts expect Roivant Sciences to post ($2.00) EPS for the current fiscal year and ($2.23) EPS for the next fiscal year.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $36.91 on Monday. The firm has a market cap of $26.66 billion, a price-to-earnings ratio of -69.64 and a beta of 1.23. The firm has a fifty day moving average price of $36.65 and a 200 day moving average price of $31.46. Roivant Sciences has a fifty-two week low of $19.30 and a fifty-two week high of $42.50.

Insider Activity

In other news, insider Mayukh Sukhatme sold 144,756 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the sale, the insider directly owned 18,630,739 shares of the company's stock, valued at $679,649,358.72. This trade represents a 0.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares of the company's stock, valued at $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,822,688 shares of company stock worth $66,176,636. 8.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Guggenheim lifted their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. HC Wainwright raised their price target on Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 24th. Finally, Bank of America reaffirmed a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $46.55.

About Roivant Sciences

Roivant Sciences Ltd. NASDAQ: ROIV is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.